Navigation path

Community Register of medicinal products

Community register of orphan medicinal products


GRANTED  

Product information

(S)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-O-[alpha-(2´´, 4´´, 5´´, 7´´-tetranitro-9´´-fluorenylideneaminooxy)propionyl]-1H-pyrano[3´, 4´, 6´, 7´]indolizino[1,2-beta]-quinoline-3, 14-(4H), 12H)-dione, hydrochloride

EU orphan designation number: EU/3/10/788   
Active ingredient: (S)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-O-[alpha-(2´´, 4´´, 5´´, 7´´-tetranitro-9´´-fluorenylideneaminooxy)propionyl]-1H-pyrano[3´, 4´, 6´, 7´]indolizino[1,2-beta]-quinoline-3, 14-(4H), 12H)-dione, hydrochloride
Indication: Treatment of hepatocellular carcinoma
Sponsor: TLC Biopharmaceuticals B.V.
Neils Bohrweg 11-13, NL-2333 CA Leiden, Nederland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/10/2010 Centralised Orphan - Designation EMA/OD/065/10 (2010)6933 of 01/10/2010
01/06/2011 Corrigendum - (2011)3909 of 30/05/2011